

PECULIARITIES OF SUPPLY AND CONSUMPTION OF STATINS IN UKRAINE

Alsawafi Salam Oudah, S.V. Zhadko
The National University of Pharmacy, Kharkiv, Ukraine
svzhadko@mail.ru

Statins are a class of drugs used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase. The best-selling statin in the world is atorvastatin. In 2003 it became the best-selling pharmaceutical in history. Launched 1997, Pfizer Inc.'s Lipitor became the best-selling statin drug just three years after its debut. It went on to become the best-selling drug in the history of pharmaceuticals. Despite losing patent protection and a growing generic market, Lipitor (which lost patent protection in late 2011), together with Merck's Zocor (whose patent expired in 2006), still accounts for 57% in USA of the 264 million cholesterol prescription pot.

At the retail pharmaceutical market of Ukraine in 2015 are registered Simvastatin (36 foreign and 4 domestic drugs), Lovastatin (1 domestic drug), Pravastatin (1 foreign drug), Fluvastatin (1 foreign drug), Atorvastatin (69 foreign and 11 domestic drugs) and Rosuvastatin (70 foreign and 2 domestic drugs). Thus, the maximum number of registered statins belongs to Atorvastatin, and Rosuvastatin subgroups (80 drugs and 72 drugs respectively).

To analyse market share and consumption of statins we used the audit data of the pharmaceutical market of the system «Pharmstandart» of the company «Morion». In 2013 at the Ukrainian pharmaceutical market were sold around 3 million of packs of lipid modifying agents amounting to 225.8 million UAH.

The market share of statins among all lipid modifying agents at the Ukrainian pharmaceutical market is 73% in volume terms and 82% in monetary terms. The largest volume of sales in physical terms as well as in monetary terms belongs to atorvastatin. Annual volume of sales of atorvastatin is around 1.4 million packs to the amount of 122.6 million UAH. At the atorvastatin segment there is original drug Liprimar (known worldwide as Lipitor) and 79 generic drugs. Original drug Liprimar takes only 2.69% of atorvastatin segment in physical terms and 10.45% in monetary terms.

Market share of foreign atorvastatin drugs is 80.52% in physical terms and 85.4% in monetary terms. The leading positions among atorvastatin in Ukraine according sales in value terms belong to generic Europe companies KRKA, Slovenia (45,12%) and Zentiva, Czech Republic (12,33%).